Fonte: Current Cancer Drug Targets. Unidade: FMRP
Assuntos: MEDULOBLASTOMA, ANÓXIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRUZEIRO, Gustavo Alencastro Veiga et al. HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation. Current Cancer Drug Targets, v. 18, n. 3, p. 287-294, 2018Tradução . . Disponível em: https://doi.org/10.2174/1568009617666170315162525. Acesso em: 16 maio 2024.APA
Cruzeiro, G. A. V., Reis, M. B. dos, Silveira, V. da S., Lira, R. C. P., Carlotti Júnior, C. G., Neder, L., et al. (2018). HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation. Current Cancer Drug Targets, 18( 3), 287-294. doi:10.2174/1568009617666170315162525NLM
Cruzeiro GAV, Reis MB dos, Silveira V da S, Lira RCP, Carlotti Júnior CG, Neder L, Oliveira RS, Yunes JA, Brandalise SR, Aguiar S, Eterovic AK, Tone LG, Scrideli CA, Valera ET. HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation [Internet]. Current Cancer Drug Targets. 2018 ; 18( 3): 287-294.[citado 2024 maio 16 ] Available from: https://doi.org/10.2174/1568009617666170315162525Vancouver
Cruzeiro GAV, Reis MB dos, Silveira V da S, Lira RCP, Carlotti Júnior CG, Neder L, Oliveira RS, Yunes JA, Brandalise SR, Aguiar S, Eterovic AK, Tone LG, Scrideli CA, Valera ET. HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation [Internet]. Current Cancer Drug Targets. 2018 ; 18( 3): 287-294.[citado 2024 maio 16 ] Available from: https://doi.org/10.2174/1568009617666170315162525
